<P>&nbsp;</P> <P align=justify>The&nbsp;<A title=CLB href="http://www.centreleonberard.fr/" target=_blank>L&#233;on-B&#233;rard Centre&nbsp;</A>(CLB), <STRONG>which specialises in the fight against</STRONG><STRONG> <A title=cancer href="https://www.aderly.com/pharmaceutique_biotech/index,p,100044,FR.jsp" target=_blank>cancer</A></STRONG>, is a leading national and international oncology hospital as well as a recognized research centre. The role of the centre is to offer quality care and access to the latest advances in research for patients suffering from cancer.<STRONG> The clinical research of the CLB has recently obtained the ISO 9 001 certification from AFNOR</STRONG>, an international certification delivery network, which testifies to the fact that the centre applies the most stringent international regulations in conducting clinical research. </P> <P align=justify>&nbsp;</P> <P align=justify>This certification is essential in order to ensure that foreign companies entrust their molecules to the L&#233;on-B&#233;rard centre, and it will allow the centre to <STRONG>pursue future collaborations with international laboratories</STRONG>, particularly the larger American laboratories. It will also allow the centre to offer its patients the very latest treatments&nbsp;before&nbsp;they become commercially available. </P> <P align=justify><BR>The CLB is one of the few French hospitals, and the only one in the Rh&#244;ne-Alpes region, to have received this certification, which involved 79 people over the course of two years. 1,291 patients (18 %) were included in a trial in 2012 and 239 tests are currently underway. The CLB conducts phase I, II, III and IV trials, mostly in medical oncology, surgery and radiotherapy. </P> <P align=justify><BR>&nbsp;</P> <P align=justify><BR>&nbsp;</P>